Skip navigation.

Surveillance of HIV Drug Resistance in Adults Initiating Antiretroviral Therapy (Pre-Treatment HIV Drug Resistance)

Corporate author: 
WHO
Publication details: 
Geneva, WHO, 2014
Abstract:

The purpose of this survey is to calculate (a) a nationally representative prevalence estimate of HIVDR among all ART initiators, and (b) a nationally representative prevalence estimate of HIVDR among initiators without prior exposure to ARV drugs (see Box 1). The size of the survey sample size (discussed in Section 4.4) has been calculated to provide sufficient statistical precision for the latter prevalence estimate. Operationally, in order to facilitate implementation, the survey will enrol all eligible individuals initiating ART during a predetermined period (see section 4.3 for patient eligibility criteria). At the same time, information on prior ARV exposure will be obtained at the time of specimen collection, and these data will then be used to stratify the sample and calculate the outcomes of interest (see Section 3).